Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-EC
2025-523877-40-00Phase 2Authorised
- Sponsor
- University College Dublin
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of tirzepatide in endometrial adenocarcinoma (2 arms), sponsored by University College Dublin. Primary endpoint: Pathological complete response rate at 12 months. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on 2025-523877-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523877-40-00.